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Immune induction by successful vaccine formulations seems to involve stimulation of both humoral and cellular arms of
immunity. Nevertheless, CD8+ CTLs are of critical relevance in the context of intracellular infection and tumor for many reasons.
The task of exerting antipathogen activity by CD8+ T cells, which principally function to control and eradicate intracellular
pathogens, is enabled by constitutive expression of MHC class-I molecules on all tissue types. CTL induction oﬀers hope for
vaccines against pathogens that are resistant to neutralizing activity. This review discusses the mechanism of immune induction
by some successful vaccines and based on the accrued evidence suggests ideas for improved design of CTL-inducing vaccines.
1.Introduction
One of medicine’s greatest triumphs has been the control
of many infectious diseases with prophylactic vaccines.
Successful vaccine formulation was conﬁrmed with smallpox
eradication and a similar outcome is expected with polio.
Measles also has been eliminated as a pathogen in most
developed countries. Highly eﬀective vaccines also exist for
mumps, varicella in children, yellow fever, hepatitis viruses
A and B, rubella, and rabies, despite the fact that large
numbers of people in the developing world fail to use them
due to cost factor and logistics. This is particularly a tragedy
with measles which is an extremely eﬀective vaccine when
used correctly in children. With many individuals remain-
ing unvaccinated, unnecessary mortality and complications
occur from measles infection.
However, several viruses are controlled by vaccines that
still need improvement, notably the vaccines for inﬂuenza.
The currently used inactivated vaccines have debatable
eﬃcacy. But the newly available attenuated vaccine, when
administered mucosally, could be more eﬀective due to an
enhanced induction of a mucosal immune response. Even
highly eﬀective vaccines, such as the yellow fever vaccine,
lack perfection because of complications in some aged
individuals [1]. Many virus infections could be controlled
by appropriately designed vaccines, yet the existence of
multiple serotypes, sporadic nature, and economic realities
may prevent this from being achieved.
Vaccines are also under advanced stages of development,
or available for Dengue Virus, West Nile Fever (WNF),
and Rift Valley fever. Of particular interest is the vaccine
developed using reverse genetics to express recombinant
proteins in the vector and the 17D attenuated Yellow Fever
virusthatareprovingtobeexcellentvaccinesforDengueand
WNF [2–5]. The Yellow Fever vaccine has been established
to induce protection against the virus itself for at least 10
years. Such successes are encouraging for additional viruses
that could be controlled by vaccines, but for many reasons
vaccines may not be available any time soon.
2. FactorsThatFavororHinder VaccineSuccess
In spite of great intellectual eﬀort and big investments, we
have failed to produce eﬀective vaccines against Human
immunodeﬁciency virus (HIV), hepatitis C virus (HCV),
respiratory syncytial virus (RSV), and all herpes viruses
(HSV) except for chicken pox (Varicella). The most diﬃcult
case of all is HIV which seems almost designed to outwit
immunologists.
Some of the factors that contribute to vaccine failure may
be common to certain pathogens (Table 1). These factors are
dynamic with evolving pathogens that negatively inﬂuence2 Journal of Biomedicine and Biotechnology
Table 1: Factors that makes control by vaccines problematic [6–9].
(i) Antigenic plasticity—all RNA viruses
(ii) Possession of immune evasion maneuvers, for example,
targeting antigen-presenting cells and lymphocytes
(iii) Persistence and latency
(iv) Entrance and major replication at mucosal surfaces
(v) Poor or retarded immune induction
(vi) Resistance to neutralization by antibody
(vii) Immunity solely dependent on T cells
Table 2: Factors that favor control by vaccines [10].
(i) Stable antigenic nature
(ii) Single host
(iii) Systemic infection
(iv) Immunity mediated by neutralizing antibody
(v) Virus removed by immune system
(vi) Agent induces long-term T and B cell memory
host competition for survival. In the case of all RNA viruses,
antigenic plasticity seems to be the key issue. Additionally,
viruses possess many tools in their armamentarium to evade
host immune response. Viruses may target the tissue they
initially infect, the sentinel cells that convey the information
to speciﬁc lymphocytes, or directly the speciﬁc T/B cells.
Pathogens may also choose to conceal themselves in cells
that are inaccessible to the immune system or, ideally, the
cells that constitute the immune system. These pathogens
collectively cause chronic, persistent, or latent infection.
The best examples are found in the virus family listed
earlier (HIV, HSV, and HCV). These pathogens are generally
resistant to neutralization by antibodies (Abs); therefore,
immunity is dependent primarily on T cells.
The factors that favor success for a vaccine against a
pathogen are the stable nature of antigens, systemic infection
involving a single host, immunity that is mediated by
neutralizing antibodies, pathogens inducing long-term high-
eﬃciency T and B cell memory if the host survives the
infection, and ﬁnally sterilizing immunity that clears the
pathogen (Table 2). The scenario which makes for highly
eﬀective control by vaccines is perhaps best illustrated by
the ﬁrst agent that was successfully controlled, smallpox.
However, the actual mechanisms involved in recovery from
infection and resistance to challenge have only recently
been identiﬁed. Such studies were done in the mouse
model of Vaccinia since work with Variola in humans is, of
course, not possible. Intriguingly, immunity to smallpox is
exceedingly durable [11, 12]. Edward Jenner, on the basis
of inoculation studies with smallpox material, demonstrated
that a patient that had natural cowpox 53 years earlier was
resistant to challenge (reviewed in [13]). Not so long ago, the
laboratories of Mark Slifka and Raﬁ Ahmed have shown that
all forms of immunity and particularly neutralizing antibody
can be detected in Vaccinia vaccines for at least 30 years and
in some instances 75 years [14–16]. Indeed Slifka’s group
estimated the half-life of humoral immunity to be about 80
years and T cell responses between 8–15 years [16]. How Abs
persist so long is perplexing. It is not explained by persistent
viruses or by exposure to other cross-reacting microbes since
no cross-reactivities with Vaccinia are known. One expects
the explanation to lie with the persistence of memory B cells
in the bone marrow.
3. Lessons from B Cell andRole of T Cells
Studies done by the Berzofsky and Bevan groups in mice
with Vaccinia have revealed several clues about mechanisms
of immunity [17, 18]. These studies serve to emphasize
the conclusion that neutralizing Abs play the predominant
role in both curtailing infection and certainly in preventing
disease following reinfection. However, the desirable Ab is a
high-aﬃnity IgG, which requires appropriate helper T cell
co-stimulation for its induction. In Vaccinia infection, the
viral immunologist’s favorite cell type—the CD8+ T cell—
appears to play a minor and possibly dispensable role. This
raises the issue of whether or not immunity to reinfection is
ever solely dependent on one or another subset of immune T
cells.
The case for CD8+ T cells in recovery from infection and
resistance to challenge was made most strongly by studies
in mice of the noncytopathic arenavirus and lymphocytic
choriomeningitis virus (LCMV) which is a cousin of Lassa
Fever Virus [19]. In this model, resolution of infection and
long-term immunity to reinfection primarily involve CD8+
T cells [20]. Recently, exciting studies on the nature and
function of antiviral memory in LCMV have provided clues
to understand memory that may have application to novel
CTL vaccine design [21].
4. Acute versus Chronic Infection Scenario
Acute infection with LCMV results in a prompt and vigorous
CD8+ T cell response that mediates rapid viral clearance.
Most of the antigen-speciﬁc T cell eﬀectors die rapidly of
apoptosis with approximately 10%–20% persisting at stable
levels indeﬁnitely [24]. These cells turn over homeostatically,
an event driven by cytokines such as IL-15 [25]. In this
system, memory sustenance is an antigen-independent event
as it seems to be the case for Vaccinia in the human
system. Nonetheless, others believe that memory changes
with time as a consequence of exposure to cross-reacting
or perhaps bystander inﬂuences [26]. Fascinating studies
by several groups have revealed that the establishment
of the long-term CD8+ T cell memory response actually
requires coinduction of CD4 helper T cells or replacement
of their function with certain costimulants or cell type [27–
29]. Curiously, memory CD8+ T cells that are induced in
the absence of help respond poorly to restimulation by
antigens. Upon restimulation, “helpless” memory CD8+ T
cells are eliminated in a TNF-related apoptosis-inducing
ligand- (TRAIL-) dependent mechanisms [30].
Perhaps of even more interest are the studies on the
nature of CD8+ T cell in memory situations in which theJournal of Biomedicine and Biotechnology 3
Table 3: Immunity to Hepatitis C Virus—A Flavivirus with no
vaccine [9, 22].
(i) 60%–80% of patients remain chronically infected and suﬀer
consequences
(ii) Patients who do recover develop multiepitope-speciﬁc CD8+
and type 1 CD4+ T cells
(iii) Neutralizing Ab production takes 6–8 months and highest
titers occur in chronics. Recovered patients may test negative
(iv) Abs always gone by 10–20y, but speciﬁc T cells persist for life
in liver (in chimps)
(v) Chimps without CD4+ or CD8+ T cells fail to control
infection
(vi) Escape mutants for Ab and T cells occur readily
virus remains as a chronic infection. Studies on chronic
memory cells in the case of persisting LCMV clone 13
infection revealed major diﬀerences from acute memory
cells. First, the chronic memory cells failed to overcome
the initial acute infection. Secondly, when transferred to an
antigen-free environment, the acute memory cells survived
and maintained their numbers by turning over homeostat-
ically, but the chronic memory cells failed to divide and
ultimately disappeared [31]. Thus, chronic memory cells
are dysfunctional when addicted by an antigen, resulting in
upregulation of some inhibitory machinery [32, 33]. Other
explanations include the induction of third-party regulatory
cells possibly in response to antigen presentation by a subset
of dendritic cells (DCs) [34, 35].
The outcomes of studies on LCMV in an animal model
raise the question of relevance to human chronic virus
infections. In this regard, the two most important human
chronic viruses are Human immunodeﬁciency virus (HIV)
and Hepatitis C virus (HCV). HCV has become a major
human pathogen and, although controlled in some by
antiviral drugs, is a major cause of chronic disease and
mortality [36]. Currently, vaccines are unavailable, and
prospects are dim to develop them soon. As summarized in
Table 3, HCV infection induces an immune response that is
usually noneﬀective and occurs late during infection. Unlike
vaccine-controllable viruses such as Vaccinia and polio,
neutralizing Abs seem to play an insigniﬁcant role in control
of infection or the prevention of reinfection [37, 38]. Indeed,
individuals who make the highest levels of neutralizing
antibody subsequently develop chronic disease [39]. HCV
appears to possess an abundance of strategies that serve to
circumvent immune defenses; these include properties that
avoid innate immunity as well as adaptive defenses (listed in
Table 4).HCV,likeHIV,isamovingtargetantigenicallysince
sequence mutants are frequent [22]. Moreover, it seems that
in some, perhaps the majority of patients, HCV stimulates
a regulatory T cell response which actually counteracts the
otherwise protective CD8 and CD4 IL-2-producing T cell
responses [40, 41]. Making an eﬀective vaccine against HCV
will require identiﬁcation of the components that induce
protective T or antibody responses and deliver them in
such a way that protective rather than regulatory responses
Table 4: Hepatitis C Immune Escape Tricks [8, 9, 23].
(i) Viral sequence mutations allow escape of both Ab and T cell
recognition (NB high replication rate)
(ii) HCV core protein binds a complement protein that results in
downregulation of IL-12 production and aﬀects T cell
induction
(iii) Express a protease which interrupts induction of interferon
a/b
(iv) Incomplete diﬀerentiation of HCV-speciﬁc T cells may occur
(like chronic memory cells)
(v) Induction of IL-10-producing Treg cells
(vi) Also an involvement of CD4+ CD25+ natural Tregs
are induced. Furthermore, there is the ever-more daunting
challenge of attempting to change response in chronically
infected individuals by changing their ineﬀective response
pattern to one that provides protection using therapeutic
vaccines.
5.Vaccine Design
HIV, HCV, and many parasitic infections represent microbes
that urgently demand eﬀective vaccines. Hopefully, this
demand can be met, but progress will likely be slow and
convoluted. The ideal solution might occur if scientists
identifysuccessfulmeansofinducingneutralizingantibodies
especially if they can be induced at the site of viral entrance.
For instance, although a vaccine for RSV is unavailable,
passive protection can be eﬀected with a monoclonal Ab
that recognizes the F protein [42]. In situations that mainly
demand a durable neutralizing antibody response, the task
should be feasible as long as sequences that encode neutraliz-
ingepitopesandhelperTcellcostimulationcanbeidentiﬁed.
Recombinant proteins administered with adjuvants work
successfully for hepatitis B [43]. More recently, the capsule
polysaccharideantigenofHemophilusinﬂuenzacoupledtoa
proteincarriergivenwithalumadjuvanthasbeenastrikingly
successful vaccine (reviewed in [44]). As mentioned, the
17D yellow fever vector holds great promise to induce IgG
antibody and may also be valuable to achieve CD8+ T cell
induction [4].
Several approaches can be used to successfully induce
CD8+ T cell responses, which are needed particularly for
protection against HIV and HCV. With regard to HIV,
al a r g en u m b e ro fd i ﬀerent live vectors given alone or
in combination with a priming dose of DNA or protein
vaccine have been evaluated in primate test systems [45,
46]. Although many model exposure systems have yielded
encouragingresults,attemptstotranslatethemtothehuman
situation have so far proven disappointing [47]. In the past,
the best vaccines have been attenuated mutants, but this
approach may not be acceptable, at least with HIV, likely
for safety reasons. Even so, such attenuated mutants appear
superior to protect nonhuman primates against a lentivirus
challenge [48].4 Journal of Biomedicine and Biotechnology
6. Need for CD8+ CTL Induction
TheimportanceofCD8+CTLsinthecontextofintracellular
infection and tumor is well established. Immune induction
by successful vaccine formulations seems to involve stim-
ulation of both humoral and cellular arms of immunity.
Nevertheless, in some diseases scenario CD8+ CTLs are
of critical relevance for the following reasons: (a) task
of exerting antipathogen activity (lysis of infected cell or
purging of infectious material by cytokine production), (b)
enabled by constitutive expression of MHC class-I molecules
on all tissue types, (c) principally function to control and
eradicate intracellular pathogens, and (d) ﬁnally oﬀering
hope for vaccine against pathogens that are resistant to
neutralizing activity.
The three main factors that determine the success of a
CTL-inducingvaccineareitsabilitytoinducehighfrequency
of virus-speciﬁc CD8+ T cells, polyfunctional CD8+ T cells,
and proximity to the site of initial infection. In other words,
the quantity, quality, and location of the memory CD8+
T cells response as discussed recently in the context of
HIV/SIV infection [49] may hold true for many other viral
infections.
An important variable is the diﬀerentiation status of
CD8+ T cell that is to be activated. Naive CD8+ T cells
are the ones that reside normally in the lymphoid tissues
and have not been exposed to antigen after emergence from
thymus. First exposure to antigens presented on MHC-
I results in primary response and is called priming. On
the other hand, memory CD8+ T cells are generated by
priming and persist long after the original priming event has
terminated. Memory CD8+ T cells reside in lymphoid tissue
and extravascular sites and respond quickly and vigorously
to reexposure. Most of the vaccine design has been targeted
to priming a response and less on memory reactivation or
rescue of defective priming.
7. Turningon CD8+T Cells
Progress in the induction of protective T cell-mediated
immunity is expected to come by using antigens given
along with the appropriate choice of adjuvants and co-
stimulators to direct and maximize immune responses. This
topic has received extensive reviews including attempts to
achieve optimal mucosal immunity [50–54] .O n ec l u ef o r
success may be to exploit the well-accepted notion that
antigen delivered by an appropriate subset of dendritic cells
represents an approach to tailor the nature and magnitude of
theimmuneresponse[55].Thusantigensloadedexvivointo
DCs of various types are expected to be useful as therapeutic
vaccines in certain cancers [56–58]. However, a more practi-
cal approach would be to ﬁnd ways of delivering antigen in
vivo selectively to appropriate types of DCs or perhaps other
antigen-presenting cells [55, 59]. Cytokine such as GM-CSF
and IL-12 as adjuvants along with antigen-loaded DC has
proven to be eﬀective in priming high-quality CD8+ T cells
in some animal models. Homeostatic cytokines that belong
to γ-chain family (IL-2, IL-7, IL-15 and IL-21) may prove
useful during recall responses or serve as eﬀective partner
(adjuvant) for therapeutic vaccine candidates [60–64].
Perhaps of particular interest are the results of the von
Andrian group which showed the apparent imprinting eﬀect
of DCs on the homing fate of antigen-speciﬁc T cells [65].
For instance, if Ag was administered into the skin, DC trans-
ported antigen to the draining LN and the speciﬁc T cells
induced mainly homed back to cutaneous sites. In contrast,
antigen arriving via the gut resulted in the induction of
gut-mucosa seeking T cells [65]. Since controlling infections
requires prompt recruitment of eﬀectors to sites of entrance,
vaccination schemes that prime for T cells that home quickly
to infected sites might tip the balance in favor of the host and
stop the infection from spreading. It will be exciting to see
whether such strategy worked for vaccine delivery.
Prophylactic vaccines have been able to do a reasonable
job in priming adequate CD8+ T cell response, yet the need
for a therapeutic vaccine to induce CD8+ T cell is more
pertinent in the context of certain chronic infections and
cancer. As suggested by Ahlers and Belyakov in a recent
review,newvaccinestrategiesthatelicithigh-avidityCD8+T
celleﬀector/memoryresponses,whicharecapableofclearing
virus-infected cells at entry sites, are required to curtail
disease manifestation. Judging at the pace of research and
the recent technological advances, eﬀective CTL-inducing
vaccines are achievable in the near future.
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